Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary
Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (a Nevada corporation with a wholly-owned Israeli subsidiary).
Reporting Period: Quarterly report for the period ended December 31, 2009 (Six months ended Dec 31, 2009).
Business Stage: Development stage company focused on adherent stromal cells production technology and cell therapy products (specifically PLX-PAD for peripheral artery disease). The company has not generated any revenues since inception.
Going Concern: The filing states there is substantial doubt about the company's ability to continue as a going concern without additional financing.
Key Financial Metrics (Six Months Ended Dec 31, 2009)
| Metric | Value (USD in thousands) |
|---|---|
| Revenue | $0 |
| Net Loss | $(3,448) |
| Net Loss Per Share (Basic/Diluted) | $(0.22) |
| Cash and Cash Equivalents (Ending) | $1,383 |
| Short-term Deposits | $2,500 |
| Total Current Assets | $4,057 |
| Total Current Liabilities | $1,057 |
| Working Capital | $3,000 |
| Accumulated Deficit (Inception to Date) | $(36,100) |
| Cash Used in Operating Activities | $(1,902) |
| Cash Used in Investing Activities | $(2,631) |
| Cash Provided by Financing Activities | $3,577 |
Material Changes vs. Prior Period
- Net Loss: Increased to $(3.45M) for the six months ended Dec 31, 2009, compared to $(3.08M) for the same period in 2008. The increase is primarily due to higher R&D expenses related to clinical trial recruitment.
- R&D Expenses (Net): Increased 39% to $1.81M (from $1.30M). This increase is attributed to the timing of grant approvals from the Israeli Office of the Chief Scientist (OCS) and increased personnel costs for clinical trials.
- General & Administrative (G&A): Decreased 4% to $1.65M (from $1.71M) due to a reduction in stock-based compensation expenses.
- Liquidity: Cash and cash equivalents decreased by $956,000 from June 30, 2009, to $1.38M at Dec 31, 2009. However, the company holds $2.5M in short-term deposits.
- Capital Structure: Significant equity issuances occurred in the period, including a $3.03M offering in October 2009 and a $0.79M offering in July 2009 triggered by clinical trial enrollment.
Guidance, Outlook, and Risks
- Clinical Progress: Phase I clinical trials for PLX-PAD are ongoing in Germany and the US. As of Jan 11, 2010, 13 patients had been enrolled, with initial data showing no significant unfavorable effects and a trend towards efficacy in three patients.
- Capital Requirements: The company estimates net operating cash expenses of approximately $6.0M for the next 12 months. Management believes current funds plus an approved $2.3M OCS grant (of which $1.23M has been received) will sustain operations until at least September 2010.
- Financing Needs: The company expects to continue raising capital through equity issuances and government grants. Future equity financing will result in dilution to existing shareholders.
- Risks:
- Substantial doubt regarding the ability to continue as a going concern.
- No assurance of profitable operations or successful product commercialization (products likely not ready for sale for at least three years).
- Reliance on the OCS grant and ability to secure additional funding.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.38M cash plus $2.5M short-term deposit against the projected $6.0M annual burn rate.
- Grant Reliance: Confirm the status and disbursement schedule of the remaining balance of the $2.3M OCS grant.
- Dilution Impact: Assess the impact of recent and potential future equity offerings on existing shareholder ownership.
- Clinical Milestones: Monitor the completion of Phase I trials and the initiation of subsequent phases to validate the commercialization timeline.
- Going Concern Status: Review the auditor's report and management's plan to address the substantial doubt regarding the company's ability to continue operations.